PLCO试验卵巢癌筛查结局:组织学异质性影响检出、过度诊断与生存
基于PLCO筛查试验随机入组的78,215名女性,分析496例卵巢癌(413例有组织学特征)的筛查结局。II型肿瘤占74%,筛查对II型肿瘤的敏感性(65% vs 86%)、早期诊断比例(15% vs 81%)更低,过度诊断率更低(28.2% vs 72.2%),且II型肿瘤特异生存更差。
要点
- 筛查对II型卵巢癌敏感性仅65%,低于其他类型的86%
- II型肿瘤筛查检出时仅15%为I/II期,其他类型为81%
- II型肿瘤过度诊断率28.2%,低于其他类型的72.2%
核心结论
- 卵巢癌筛查对II型与其他类型肿瘤的筛查特征不同
- II型肿瘤更不易被筛查发现、诊断时分期更晚、过度诊断率更低
- 筛查未改善II型或其他类型卵巢癌的特异生存
研究设计与样本
- 前列腺、肺、结直肠和卵巢筛查试验(PLCO)筛查组女性每年接受CA-125和经阴道超声检查3-5年
- 随机入组78,215名女性,496例诊断为卵巢癌,413例(83%)肿瘤有组织学特征
- 按肿瘤类型(II型 vs 其他)和研究组(筛查组 vs 常规组)比较筛查特征与结局
主要发现
- 496例卵巢癌中,有组织学特征的413例里II型占74%(305例),其他类型占26%(108例)
- 筛查组中II型肿瘤占70%,常规组中占78%(p=0.09)
- 筛查组内,II型肿瘤筛查检出率29%,其他类型为54%(p<0.01)
- 筛查敏感性II型为65%,其他类型为86%(p=0.02)
- 筛查检出的II型肿瘤中I/II期占15%,其他类型为81%(p<0.01)
关键数值与推荐
- 筛查敏感性:II型65% vs 其他86%(p=0.02)
- 筛查检出时I/II期比例:II型15% vs 其他81%(p<0.01)
- 过度诊断率:II型28.2% vs 其他72.2%(p<0.01)
临床怎么用
- 现有CA-125联合经阴道超声筛查对II型卵巢癌敏感性有限,易漏诊
- 筛查检出的II型卵巢癌多为晚期,且过度诊断率低,提示筛查获益有限
- 临床咨询时应告知患者筛查对侵袭性强的II型肿瘤检出能力不足
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: A mortality benefit from screening for ovarian cancer has never been demonstrated. The aim of this study was to evaluate the screening outcomes for different histologic subtypes of ovarian cancers. METHODS: Women in the screening arm of the Prostate, Lung, Colorectal and Ovarian Screening Trial underwent CA-125 and transvaginal ultrasound annually for 3-5 years. We compared screening test characteristics (including overdiagnosis) and outcomes by tumour type (type II versus other) and study arm (screening versus usual care). RESULTS: Of 78,215 women randomised, 496 women were diagnosed with ovarian cancer. Of the tumours that were characterised (n = 413; 83%), 74% (n = 305) were type II versus 26% other (n = 108). Among screened patients, 70% of tumours were type II compared to 78% in usual care (p = 0.09). Within the screening arm, 29% of type II tumours were screen detected compared to 54% of the others (p < 0.01). The sensitivity of screening was 65% for type II tumours versus 86% for other types (p = 0.02). 15% of type II screen-detected tumours were stage I/II, compared to 81% of other tumours (p < 0.01). The overdiagnosis rate was lower for type II compared to other tumours (28.2% versus 72.2%; p < 0.01). Ovarian cancer-specific survival was worse for type II tumours compared to others (p < 0.01). Survival was similar for type II (p = 0.74) or other types (p = 0.32) regardless of study arm. CONCLUSIONS: Test characteristics of screening for ovarian cancer differed for type II tumours compared to other ovarian tumours. Type II tumours were less likely to be screen diagnosed, early stage at diagnosis or overdiagnosed.
引用
- Temkin SM, Miller EA, Samimi G, et al. Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival. Eur J Cancer. 2017. PMID: 29156299. doi:10.1016/j.ejca.2017.10.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。